Immunovant
Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of targeted immunotherapies for autoimmune diseases. The company utilizes its proprietary antibody technology platform to develop batoclimab and IMVT-1402, which are novel neonatal Fc receptor inhibitors designed to reduce pathogenic IgG antibodies in autoimmune conditions. Its clinical development pipeline addresses severe autoimmune indications across neurology, rheumatology, and dermatology. Core operations encompass preclinical drug discovery, protein engineering, clinical trial management, and biotechnology research. As a clinical-stage development firm, the company generates minimal commercial revenue and finances its operations through public equity financing and parent-backed capital support. Immunovant holds an emerging position in targeted immunological drug development. The company is headquartered in New York City, United States, and its common stock trades on the Nasdaq Global Market.
4 of the funds FundTelligence covers report a position in Immunovant.
- Legal name
- Immunovant Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Immunovant
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.4 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)